Specialized news

                        Array
(
    [0] => stdClass Object
        (
            [id] => 1425
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => fe1133a3ddce5c9005df.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 0
            [displayed_time] => 2026-04-16
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2026-04-16 09:33:00
            [updated_time] => 2026-04-17 15:22:09
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => Genetic-testing-ecosystem-in-reproductive-support-at-Eurofins-GENTIS
            [title] => Genetic testing ecosystem in reproductive support at Eurofins GENTIS
            [description] => The journey of finding and welcoming a child is one of the most sacred milestones for every family. However, alongside happiness comes many concerns, especially those related to reproductive health and genetic factors that may affect fertility and fetal development. In this context, proactive testing, screening, and early detection of potential risks play an essential role.
            [content] => 
Understanding this need, Eurofins GENTIS has developed a comprehensive, scientific, and specialized genetic testing ecosystem for reproductive support. This system is designed to accompany couples at every stage – from preconception, through assisted reproduction, to pregnancy monitoring – helping optimize the chances of having a healthy baby.
Testing for both partners – the foundation for a strong start

 Before beginning the journey to parenthood, a comprehensive assessment of reproductive health and genetic risks for both partners is essential. This is a critical first step to detect early abnormalities that may affect fertility or be passed on to the next generation.
Testing for men focuses on evaluating sperm quality, genetic structure, and fertility-related factors. Key tests include:

AZF: detects Y chromosome microdeletions – a common cause of male infertility
Sperm DNA fragmentation: evaluates DNA damage in sperm
Ultragen: screens for genetic disorders
CFTR gene: identifies risks related to cystic fibrosis
Karyotyping: detects chromosomal abnormalities in number and structure
Thalassemia screening
Carrier screening panel of 28 recessive genes

Testing for women not only evaluates fertility but also identifies factors that may affect pregnancy:

AMH: assesses ovarian reserve
HPV: screens for viruses causing
Cervical cancer
Karyotyping
Thalassemia screening
STDs: screening for sexually transmitted diseases
FSHR gene: related to ovarian stimulation response
NK test: evaluates immune cell activity
Thrombophilia: assesses inherited clotting disorders
Ultragen
Carrier screening panel of 28 recessive genes

Completing these tests provides doctors with a comprehensive understanding, enabling them to design the most appropriate and personalized treatment and reproductive support plan for each couple.
Embryo testing and implantation conditions – optimizing success rates

 In modern assisted reproductive techniques such as in vitro fertilization (IVF), selecting healthy embryos and ensuring optimal uterine conditions are key factors determining success.
Embryo testing at Eurofins GENTIS analyzes the genetic material of embryos before transfer, helping select those with the best developmental potential:

PGT-A/SR: screens for chromosomal number and structural abnormalities
PGT-M: detects single-gene disorders
PGT-One, PGT-MAX 1, PGT-NEXT,
PGT-Upgrade, PGT-FAST: optimized testing packages based on different needs
ASEM test (non-invasive PGT): a non-invasive method that minimizes impact on embryos

At the same time, testing for implantation conditions plays an important role in evaluating uterine receptivity:

Genratest: analyzes gene expression related to embryo implantation
PMTest: evaluates the implantation window to determine the optimal embryo transfer timing

The combination of embryo testing and uterine condition assessment can significantly improve IVF success rates while reducing the risk of miscarriage or implantation failure.
Maternal and fetal health testing – comprehensive pregnancy protection

 After successful conception, monitoring maternal health and fetal development is an essential next step. Tests during this stage help detect early complications and genetic abnormalities in the fetus.
Key tests include:

Preeclampsia screening: identifies risks of serious pregnancy complications
Antiphospholipid testing: detects conditions increasing the risk of miscarriage and thrombosis
NIPT (GenBasic/GenEva): non-invasive prenatal testing to detect common chromosomal abnormalities such as Down syndrome, Edwards syndrome, and Patau syndrome
Newborn screening
Pediatric testing

These tests not only protect maternal health but also ensure close monitoring of fetal development, enabling timely intervention when necessary.
Comprehensive support – enhancing the health of future generations

 With a diverse and specialized testing ecosystem built for each stage, Eurofins GENTIS provides a comprehensive solution for reproductive support. Beyond testing services, the company also accompanies families through consultation, guidance, and personalized reproductive health planning.
From preconception preparation and IVF support to pregnancy monitoring, each test serves as an important “piece of the puzzle,” contributing to a safer and more complete journey for both mother and baby.
Proactive testing is the best way to protect your child’s future from the very beginning. By understanding health status and genetic risks, couples can make informed decisions with confidence, aiming for a healthy pregnancy and a higher-quality future generation.
For detailed consultation on the appropriate testing pathway, please contact hotline: 1800 2010
            [content_more] => 
            [meta_title] => Genetic testing ecosystem in reproductive support at Eurofins GENTIS
            [meta_description] => The journey of finding and welcoming a child is one of the most sacred milestones for every family. However, alongside happiness comes many concerns, especially those related to reproductive health and genetic factors that may affect fertility and fetal d
            [meta_keyword] => Supported ,Reproductive support tests
            [thumbnail_alt] => 
            [post_id] => 1425
            [category_id] => 15
        )

    [1] => stdClass Object
        (
            [id] => 1420
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => 662590122_1355653503266504_425643942896189024_n.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 0
            [displayed_time] => 2026-04-06
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2026-04-06 10:31:16
            [updated_time] => 2026-04-16 10:09:47
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => Eurofins-GENTIS-partners-with-Hanoi-Andrology-and-Infertility-Hospital-to-organize-the-April-prenatal-class
            [title] => Eurofins GENTIS partners with Hanoi Andrology and Infertility Hospital to organize the April prenatal class
            [description] => Pregnancy is a sacred journey but also comes with many concerns. Preparing knowledge and mental readiness before childbirth plays a crucial role for every expectant mother. Understanding this, Eurofins GENTIS collaborated with Hanoi Andrology and Infertility Hospital to organize a prenatal class, creating a space for sharing, connection, and meaningful support for mothers approaching motherhood.

            [content] => 
The program took place at 9:00 AM on April 4, 2026, on the 2nd floor, Building B – antenatal clinic area, Hanoi Andrology and Infertility Hospital. This was not just a regular class but also an opportunity for expectant mothers to gain essential knowledge, build confidence, and prepare for the upcoming childbirth journey.

A new space – a warmer and more intimate experience
 The AF HANOI prenatal class, in collaboration with Happy Home Association – AF HANOI, has officially returned with a new look. This time, the class was held in a completely new space – cozy, friendly, and better designed to meet the needs of expectant mothers.

The venue on the 2nd floor, Building B – antenatal clinic area offers a gentle, private atmosphere while maintaining professionalism. Here, mothers come not only to learn but also to relax, chat, and connect with others on the same journey. A weekend morning becomes more meaningful when expectant mothers can ease their minds, share emotions, and receive empathy from the community.
Learning alongside experts – practical and applicable knowledge
 One of the highlights of the prenatal class is the participation of experienced experts in obstetrics, nutrition, and newborn care. The program content is well-structured and closely aligned with the real needs of expectant mothers, helping them not only understand but also apply knowledge in daily life.
During the session, head nurse Kieu Thi Mai shared insights on physiological changes during pregnancy, how to build a balanced and nutritious diet, suitable exercises for each stage, mental health care during pregnancy, and early recognition of abnormal signs that require medical attention.

Beyond theory, the class encouraged two-way interaction, allowing mothers to ask questions directly and receive answers from experts. This approach makes the knowledge more relatable and easier to absorb.
More than a class – a community
 One of the greatest values of the prenatal class is connection. Here, expectant mothers have the opportunity to meet, get to know, and share with others going through the same special stage of life.
Stories about first-time pregnancy, concerns before childbirth, and personal experiences are openly shared. This helps mothers feel less alone, reducing pressure and anxiety.
In addition, the presence of Happy Home Association – AF HANOI contributes to creating a friendly environment where participants can find long-term support and companionship, not only during pregnancy but also after the baby is born.
A solid foundation for the journey to motherhood
 Pregnancy and childbirth are emotional journeys but also come with many challenges. Being well-equipped with knowledge not only boosts confidence but also helps ensure the safety of both mother and baby.
Through the prenatal class, Eurofins GENTIS aims to provide a comprehensive solution to help expectant mothers prepare both physically and mentally. This serves as an important foundation for a smoother and more proactive childbirth experience.
Beyond a single session, the program is held weekly with diverse topics, meeting the increasing needs of modern expectant mothers. This allows them to continuously update their knowledge and monitor changes throughout each stage of pregnancy.
With all these practical benefits, the prenatal class is truly an ideal destination for expectant mothers preparing to welcome their little angels.
            [content_more] => 
            [meta_title] => Eurofins GENTIS partners with Hanoi Andrology and Infertility Hospital to organize the April prenata
            [meta_description] => Pregnancy is a sacred journey but also comes with many concerns. Preparing knowledge and mental readiness before childbirth plays a crucial role for every expectant mother. Understanding this, Eurofins GENTIS collaborated with Hanoi Andrology and Infertil
            [meta_keyword] => Gentis
            [thumbnail_alt] => 
            [post_id] => 1420
            [category_id] => 15
        )

    [2] => stdClass Object
        (
            [id] => 1419
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => f403e2bd31f8b0a6e9e9.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 0
            [displayed_time] => 2026-03-30
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2026-03-30 15:52:20
            [updated_time] => 2026-04-16 10:05:34
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => Enhancing-IVF-efficiency-and-success-through-genetic-testing
            [title] => Enhancing IVF efficiency and success through genetic testing
            [description] => Infertility is becoming a major challenge in modern reproductive medicine as its prevalence continues to rise globally.
            [content] => 
Dr Pham Dinh Minh presented at the workshop “Advances in Reproductive Medicine 13” organized by the Hanoi Society for Reproductive Support
Causes of infertility
 At the workshop “Advances in Reproductive Medicine 13”, Dr Pham Dinh Minh – R&D Director of Eurofins GENTIS – shared scientific insights on the role of genetic testing in reproductive support. According to him, the causes of infertility can be divided into three main groups.
Dr Pham Dinh Minh shared the main groups of infertility causes

 Female infertility (around 40%) is often associated with disorders in the female reproductive system such as ovulatory dysfunction (polycystic ovary syndrome – PCOS), premature ovarian insufficiency, hormonal imbalances, fallopian tube abnormalities, or uterine and cervical conditions.

 Male infertility (around 40%) is mainly related to sperm quality and function, including abnormalities in sperm count or quality, varicocele, hormonal disorders, genetic causes, or obstruction of the reproductive tract.

 The remaining 20% may involve combined factors such as unexplained infertility, lifestyle and environmental influences, or age-related factors. In many cases, multiple causes may coexist, making diagnosis and treatment more complex.
Factors affecting IVF success rates
 In addition to identifying the causes of infertility, IVF success rates depend on multiple factors.
According to Dr Pham Dinh Minh, key factors include maternal age, embryo quality, uterine health, causes of infertility, lifestyle and psychological condition of the patient, ovarian stimulation protocols, and laboratory conditions. Among these, embryo quality and genetic factors are considered especially critical, as they directly affect implantation and fetal development.
“In many cases, embryos may carry genetic abnormalities that cannot be detected through morphological assessment alone. The application of genetic testing helps select healthy embryos, thereby improving IVF success rates and reducing miscarriage risk,” Dr Pham Dinh Minh shared.
Genetic testing helps identify causes and optimize IVF treatment
 Depending on clinical findings, infertile patients should undergo genetic evaluation and appropriate testing. Importantly, all genetic analyses should be accompanied by counseling from clinical genetic specialists for both men and women, helping couples better understand their reproductive health status.
During fertility evaluation and treatment, several tests may be indicated to identify causes of infertility, including AZF, sperm DNA fragmentation, CFTR gene testing, karyotyping, thalassemia screening, AMH, HPV, STDs, FSHR gene, and NK cell testing. These tests provide a more comprehensive view of the patient’s reproductive health, enabling physicians to design personalized and effective treatment strategies.
Dr Minh shared about the genetic testing ecosystem in reproductive support at Eurofins GENTIS
A major advancement in reproductive medicine is preimplantation genetic testing of embryos before transfer. Tests such as PGT-A/SR, PGT-M, PGT-One, PGT-MAX 1, and PGT-Upgrade allow detection of chromosomal abnormalities or single-gene disorders at the embryo stage. This enables clinicians to select embryos with the highest developmental potential, improving implantation rates, reducing miscarriage risk, and increasing the likelihood of a healthy birth.
In addition, new technologies such as ASEM test (non-invasive PGT) are being researched and applied to further optimize embryo selection in IVF.
Beyond infertility treatment, genetic testing also plays a key role in preventing hereditary diseases in future generations. Carrier screening tests, such as GEN28 (a panel screening 28 recessive disease genes), help identify the risk of couples carrying the same recessive genetic condition.
According to Dr Minh, preconception and premarital genetic screening enables couples to be more proactive in family planning, reduce the risk of having children with genetic disorders, and optimize assisted reproductive treatment when needed.
A comprehensive genetic testing ecosystem supporting IVF
 To enhance the effectiveness of infertility treatment, Eurofins GENTIS has developed a comprehensive genetic testing ecosystem that supports couples throughout their reproductive journey. This ecosystem includes premarital and preconception screening, testing to identify causes of infertility, embryo genetic testing in IVF, prenatal screening, and newborn screening.
By integrating advanced testing technologies with specialized genetic counseling systems, these solutions help personalize treatment, support more accurate clinical decisions, and improve the success rates of IVF cycles.
In the context of rapid scientific and technological advancement, genetic testing is opening new opportunities for reproductive medicine. It not only improves infertility treatment outcomes but also brings hope for parenthood to many families while protecting the health of future generations.
            [content_more] => 
            [meta_title] => Enhancing IVF efficiency and success through genetic testing
            [meta_description] => Infertility is becoming a major challenge in modern reproductive medicine as its prevalence continues to rise globally. In this context, the application of genomic technologies and genetic testing is emerging as an important approach to identify causes of
            [meta_keyword] => GENTIS
            [thumbnail_alt] => 
            [post_id] => 1419
            [category_id] => 15
        )

    [3] => stdClass Object
        (
            [id] => 1418
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => dsc03012.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 0
            [displayed_time] => 2026-03-29
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2026-03-30 09:04:09
            [updated_time] => 2026-04-16 10:00:17
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => Eurofins-GENTIS-participates-in-the-workshop-Advances-in-Reproductive-Medicine-13-updating-solutions-to-improve-IVF-success-rates
            [title] => Eurofins GENTIS participates in the workshop “Advances in Reproductive Medicine 13”: updating solutions to improve IVF success rates
            [description] => On March 28, 2026, at Melia Hanoi Hotel, the Hanoi Society for Reproductive Support successfully organized the scientific workshop “Advances in Reproductive Medicine 13” with the main theme: “How to improve the success rate of IVF cycles”. 
            [content] => 
A prestigious scientific forum in the field of reproductive support
 Amid the increasing rate of infertility and the growing demand for access to modern assisted reproductive technologies, this year’s workshop holds special significance. It is not only a place to update the latest advances in reproductive medicine but also serves as a scientific forum for experts to exchange practical experience and share optimal solutions to improve treatment outcomes.

With well-structured content, the workshop included multiple in-depth sessions focusing on key factors affecting the success rate of in vitro fertilization (IVF). The presentations were not limited to theory but closely linked to clinical practice, helping participants gain a comprehensive view and apply knowledge effectively in their professional work.
One of the highlights of the workshop was the participation of many reputable domestic and international experts. Scientific reports presented by experienced professionals provided multidimensional perspectives and updated the latest trends in reproductive support.

In addition, open discussion sessions created opportunities for delegates to interact directly, ask questions, and analyze specific clinical cases together. This is the core value of the workshop – a place to connect knowledge and promote the overall development of the field.
Eurofins GENTIS actively participates and strengthens professional connections
 
At this workshop, Eurofins GENTIS was represented by a team of experts including Dr. Nguyen Quang Vinh, Dr. Pham Dinh Minh, and Mr. Hoang Dinh Khiem. Their presence not only demonstrated a proactive spirit in learning and updating knowledge but also affirmed the organization’s active role in the reproductive medicine community.
Through the event, Eurofins GENTIS experts had the opportunity to meet, exchange ideas, and connect with many colleagues in obstetrics, gynecology, and reproductive support. This serves as an important foundation for expanding professional collaboration, while sharing practical experience to improve the quality of testing and treatment services.
The workshop “Advances in Reproductive Medicine 13” delivered valuable content focusing on trends and advanced technologies in reproductive support. Some key topics included:
- Application of new technologies in embryo culture and selection
- The role of genetics in optimizing IVF outcomes
- Personalized treatment strategies for infertile patients
- Practical experience in improving implantation and successful pregnancy rates

These topics not only updated knowledge but also provided practical solutions that can be directly applied to treatment processes, contributing to improved efficiency for reproductive support centers.
Highlights from Eurofins GENTIS presentation

 One of the key highlights of the workshop was the presentation by Dr. Pham Dinh Minh – R&D Director of Eurofins GENTIS, in session 2 with the topic: “Genetics and new technologies in reproductive support”. The presentation titled: “Enhancing IVF efficiency and success through genetic testing” attracted significant attention from participants.

In his presentation, Dr. Pham Dinh Minh shared the latest updates on the role of genetic testing in assisted reproduction. In particular, preimplantation genetic testing (PGT) was emphasized as an effective solution to:
- Detect chromosomal abnormalities early
- Select healthy embryos to improve implantation potential
- Reduce the risk of miscarriage and genetic disorders
- Optimize IVF cycle success rates
The presentation was not only highly academic but also had clear practical application, helping clinicians gain additional evidence to make appropriate treatment decisions for each patient.

Eurofins GENTIS’s presentation received positive feedback from participants. Many experts appreciated the up-to-date, scientific, and practical value of the content. Discussions and questions around genetics reflected the growing interest of the medical community in this field. This also highlights an inevitable trend in modern medicine: personalized treatment based on genetic foundations to achieve optimal outcomes for patients.
Affirming a sustainable development direction
 Participation in prestigious scientific workshops such as “Advances in Reproductive Medicine 13” clearly demonstrates Eurofins GENTIS’s development orientation: continuous learning, technological updates, and improvement of professional quality.
In the context of rapidly advancing medicine, continuously updating knowledge and technology is essential to maintain service quality. Eurofins GENTIS understands that only by leading in innovation and scientific application can it deliver the best value to customers and the community.

Through training activities, workshops, and professional collaborations, Eurofins GENTIS not only enhances its internal capabilities but also contributes to knowledge sharing and the overall development of reproductive medicine in Vietnam.
In the future, Eurofins GENTIS will continue to promote research and application of advanced genetic testing solutions, working alongside doctors and reproductive centers to improve treatment outcomes and bring the opportunity of parenthood to more families.

This event was not just a scientific workshop but also a testament to the spirit of collaboration, innovation, and continuous development within the reproductive medicine community. With its positive contributions, Eurofins GENTIS continues to affirm its role as one of the pioneers in genetic testing, accompanying the mission of improving population quality and reproductive health in Vietnam.
            [content_more] => 
            [meta_title] => Eurofins GENTIS participates in the workshop “Advances in Reproductive Medicine 13”: updating soluti
            [meta_description] => On March 28, 2026, at Melia Hanoi Hotel, the Hanoi Society for Reproductive Support successfully organized the scientific workshop “Advances in Reproductive Medicine 13” with the main theme: “How to improve the success rate of IVF cycles”. This is one of 
            [meta_keyword] => GENTIS
            [thumbnail_alt] => 
            [post_id] => 1418
            [category_id] => 15
        )

    [4] => stdClass Object
        (
            [id] => 1417
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => 800x600-web-1.png
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 0
            [displayed_time] => 2026-03-19
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2026-03-19 08:42:43
            [updated_time] => 2026-03-24 15:16:17
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => Eurofins-GENTIS-will-present-at-the-workshop-advances-in-reproductive-medicine-13
            [title] => Eurofins GENTIS will present at the workshop “Advances in Reproductive Medicine 13”
            [description] => On March 28, 2026, at Melia Hanoi Hotel, the Hanoi Society for Reproductive Support will organize the scientific workshop “Advances in Reproductive Medicine 13” with the theme: “How to improve IVF cycle success rates.” This is one of the most important annual academic events in the field of reproductive support in Vietnam, attracting significant attention from doctors, scientists, embryologists, and healthcare managers in reproductive medicine.
            [content] => 
In the context of the increasing demand for infertility treatment, along with the rapid development of biotechnology and genetics, updating scientific advances and sharing practical experience in IVF (in vitro fertilization) treatment has become especially essential. The workshop “Advances in Reproductive Medicine 13” is organized to create a prestigious scientific forum where leading experts can discuss new trends, current challenges, and solutions to improve treatment outcomes in reproductive support.

An academic forum gathering leading experts in reproductive support
 According to the agenda, the workshop will include 4 in-depth scientific sessions focusing on key topics in current reproductive practice, including:
- Ovarian stimulation
- Genetics and new technologies in reproductive support
- Quality management in reproductive support
- Risk management and quality improvement
The discussion sessions are designed to provide a comprehensive perspective on factors affecting IVF success rates, from clinical strategies and advanced testing technologies to quality management systems and risk control in laboratories and reproductive centers.
In particular, the second session, themed “Genetics and new technologies in reproductive support,” is expected to deliver updated insights into the role of genetic testing techniques, sequencing technologies, and genetic applications in improving infertility treatment outcomes.
PhD Pham Dinh Minh to present on gene testing applications in IVF
 At Session 2: “Genetics and new technologies in reproductive support,” PhD Pham Dinh Minh – R&D Director of Eurofins GENTIS will present a report titled: “Enhancing IVF efficiency and success rates through gene testing and genetics.” The presentation will take place from 10:15 to 12:00 on March 28, 2026, at Melia Hanoi Hotel.
In recent years, gene testing techniques and genetic analysis have become an essential part of reproductive medicine. Advances in next-generation sequencing (NGS) and modern genetic analysis methods allow early detection of genetic abnormalities, enabling clinicians to make more precise treatment decisions.

The application of genetic testing in IVF can bring several benefits such as:
- Screening for chromosomal abnormalities in embryos
- Detecting hereditary diseases that may be passed to future generations
- Optimizing embryo selection for transfer
- Improving implantation potential and pregnancy success rates
Through this presentation, PhD Pham Dinh Minh will share the latest updates on genetic testing technologies in reproductive support and analyze how these methods can contribute to improving IVF treatment outcomes in clinical practice.
An experienced expert in genetics and omics sciences
 PhD Pham Dinh Minh is a scientist with many years of experience in Biochemistry, Omics sciences, Genetics, and medical testing. With over 10 years of experience in teaching and research, he has participated in numerous domestic and international scientific projects, making significant contributions to the development of biotechnology applications in medicine.
In terms of scientific publications, Dr. Minh is the author and co-author of more than 45 scientific papers, including over 23 articles published in international journals. His research focuses on applications of nanobiotechnology, genome analysis, and innovative technological solutions for disease diagnosis and treatment.
Additionally, Dr. Minh is the lead author of one book chapter and co-author of another chapter in a monograph on nanobiotechnology published by Wiley in 2023—one of the world’s most reputable scientific publishers.
In research activities, he is currently the principal investigator of one national-level project funded by Nafosted and two projects under the Ministry of Science and Technology related to nanobiotechnology and stem cells. He also serves as a key member in two international collaborative projects and two national-level projects.
Beyond research, Dr. Minh is actively involved in scientific training. He has supervised 1 PhD candidate, 5 master’s students, and 6 bachelor’s students, contributing to the development of the next generation of scientists in biotechnology and genetics.
Opportunities for knowledge update and professional networking
 The workshop “Advances in Reproductive Medicine 13” is expected to provide valuable scientific insights, helping doctors and specialists stay updated with the latest trends in reproductive medicine.
The participation of leading experts and in-depth presentations will create opportunities for delegates to exchange experiences, discuss clinical challenges, and explore solutions to improve IVF success rates.
For doctors, embryologists, and researchers in reproductive medicine, this is also an important occasion for professional networking, sharing practical experience, and accessing new technologies in infertility diagnosis and treatment.
With its highly practical theme and numerous specialized reports, the workshop promises to contribute to the development of reproductive support in Vietnam and open new approaches to enhance treatment effectiveness for patients.
We look forward to welcoming doctors and experts at the workshop “Advances in Reproductive Medicine 13” and encourage you not to miss the presentation by PhD Pham Dinh Minh on the application of gene testing and genetics in improving IVF outcomes.
            [content_more] => 
            [meta_title] => Eurofins GENTIS will present at the workshop “Advances in Reproductive Medicine 13”
            [meta_description] => On March 28, 2026, at Melia Hanoi Hotel, the Hanoi Society for Reproductive Support will organize the scientific workshop “Advances in Reproductive Medicine 13” with the theme: “How to improve IVF cycle success rates.” This is one of the most important an
            [meta_keyword] => Gentis,Hasar
            [thumbnail_alt] => 
            [post_id] => 1417
            [category_id] => 15
        )

    [5] => stdClass Object
        (
            [id] => 1415
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => 800x600-web.png
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 1
            [displayed_time] => 2026-03-13
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2026-03-13 14:02:45
            [updated_time] => 2026-03-13 14:06:08
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => Eurofins-GENTIS-launches-PGT-FAST-Embryo-genetic-screening-solution-with-outstanding-turnaround-time
            [title] => Eurofins GENTIS launches PGT-FAST – Embryo genetic screening solution with outstanding turnaround time
            [description] => In recent years, advancements in assisted reproductive technologies have provided the opportunity for millions of couples worldwide to become parents. However, beyond creating embryos through in vitro fertilization (IVF), selecting embryos with good genetic quality remains a crucial factor in achieving successful pregnancies. Numerous studies have shown that chromosomal abnormalities in embryos are among the common causes of implantation failure, early miscarriage, or genetic syndromes in children after birth. Therefore, preimplantation genetic testing (PGT) has become increasingly important in modern IVF procedures. To support fertility centers in optimizing embryo selection, Eurofins GENTIS has launched a new test, PGT-FAST – an embryo genetic screening solution with the outstanding advantage of delivering results in just 15 hours.
            [content] => 

Comprehensive Chromosome Analysis for Embryo Genetic Screening
 PGT-FAST is a preimplantation genetic test performed before embryo transfer during IVF. By analyzing embryonic cells, the test evaluates the chromosomal status of embryos and detects abnormalities that may affect pregnancy development. The test allows for the analysis of all 24 chromosomes in the embryo, identifying numerical chromosomal abnormalities, also known as aneuploidy. These abnormalities can lead to serious genetic syndromes or prevent normal embryo development.
In addition, PGT-FAST can detect large structural chromosomal abnormalities, such as deletions or duplications of 5Mb or larger. These abnormalities may be associated with genetic syndromes that impact the health and development of the child. Embryo genetic screening provides fertility specialists with scientific evidence to select embryos with normal chromosomal complements, thereby increasing implantation rates and improving IVF treatment outcomes.
Significantly Reduced Turnaround Time
 One of the most notable features of PGT-FAST is its ability to significantly shorten analysis and reporting time. The optimized process allows results to be delivered within 15 hours from sample analysis. Rapid turnaround time offers practical benefits for both fertility centers and patients. Physicians can access embryo genetic results more quickly, enabling timely and appropriate clinical decisions during treatment. For many couples undergoing IVF, a shorter waiting period also helps reduce psychological stress and provides greater control over their treatment plan.
Application of Next-Generation Sequencing Technology
 PGT-FAST is based on Next Generation Sequencing (NGS), one of the most advanced and accurate genetic analysis technologies available today. The sequencing system used in this test is based on the Illumina platform (USA), combined with specialized genetic data analysis software, enabling highly accurate detection of abnormalities. The test achieves high sensitivity and specificity, ensuring reliable results for embryo genetic analysis. Utilizing modern analytical technologies not only improves test accuracy but also optimizes processes and reduces turnaround time.
The introduction of PGT-FAST represents another step forward in expanding Eurofins GENTIS’ genetic testing ecosystem in the field of assisted reproduction. This new testing solution is expected to provide fast, accurate, and efficient options for IVF centers and families seeking the opportunity to welcome healthy babies.
In an era where reproductive medicine increasingly emphasizes genetic factors, the development of advanced testing solutions like PGT-FAST is expected to further enhance treatment quality and help families move closer to their dream of becoming parents.
            [content_more] => 
            [meta_title] => Eurofins GENTIS launches PGT-FAST – Embryo genetic screening solution with outstanding turnaround ti
            [meta_description] => To support fertility centers in optimizing embryo selection, Eurofins GENTIS has launched a new test, PGT-FAST – an embryo genetic screening solution with the outstanding advantage of delivering results in just 15 hours.
            [meta_keyword] => GENTIS,PGT-FAST
            [thumbnail_alt] => 
            [post_id] => 1415
            [category_id] => 15
        )

    [6] => stdClass Object
        (
            [id] => 1414
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => z7616146207741_e7cffc3f616d1b8d7390f14ae1bddc50.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 1
            [displayed_time] => 2026-03-13
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2026-03-13 13:33:19
            [updated_time] => 2026-03-13 16:35:38
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => Eurofins-GENTIS-updates-PGT-FAST-and-GEN28-tests-at-Hanoi-General-Hospital-IVF-center
            [title] => Eurofins GENTIS updates PGT-FAST and GEN28 tests at Hanoi General Hospital IVF center
            [description] => Recently, a delegation of experts from Eurofins GENTIS, led by Dr. Nguyen Quang Vinh (Director of Eurofins GENTIS Testing Center), held a professional working session with the doctors and nurses of the Hanoi General Hospital Assisted Reproduction Center. This collaboration aims to update the latest advances in genetic testing, thereby contributing to improved treatment outcomes for families facing infertility. The session also opened opportunities for academic exchange and laid the groundwork for deeper cooperation between the two units in the future.
            [content] => 
The Eurofins GENTIS delegation was welcomed by MSc. MD. Nguyen Duy Phuong – Director of the Assisted Reproduction and Gender Medicine Center, along with doctors, nurses, and technicians from the hospital.

During the session, Pharmacist Duong Thi Phuong (Product Management Specialist at Eurofins GENTIS) presented an overview of PGT-FAST, the most advanced pre-implantation genetic screening test currently developed by Eurofins GENTIS. PGT-FAST is a pre-implantation genetic test performed before embryo transfer in the IVF process, helping assisted reproduction centers select embryos with high genetic quality. The test analyzes embryonic cells to assess genetic status and surveys all 24 chromosomes to detect chromosomal abnormalities (aneuploidy) – a common cause of implantation failure, early miscarriage, or genetic syndromes in newborns.
In addition, PGT-FAST can detect large structural chromosomal abnormalities such as deletions or duplications of 5Mb or more. The test is implemented using next-generation sequencing (NGS) technology on the Illumina platform, combined with advanced genetic data analysis software, ensuring high sensitivity, specificity, and accuracy in embryo genetic analysis.
A notable advantage of PGT-FAST is its rapid turnaround time, taking only about 15 hours from sample analysis to result. This allows doctors to access embryo genetic results quickly and make timely clinical decisions during the IVF cycle.
Alongside PGT-FAST, Pharmacist Phuong also introduced GEN28, a screening service for carriers of common genetic diseases. GEN28 screens 28 severe recessive genetic disease genes, detecting carriers even if they are completely healthy. The test uses NGS technology combined with advanced bioinformatics analysis to identify gene variants that may be passed to the next generation. With only 2–3 ml of whole blood, GEN28 can screen 28 genes associated with 25 genetic diseases and syndromes, including Thalassemia, G6PD deficiency, cystic fibrosis, Tay–Sachs disease, Wilson disease, galactose metabolism disorders, and more. These conditions can have serious, long-term impacts on health and quality of life.

Information on PGT-FAST and GEN28 received great attention from the medical team at Hanoi General Hospital IVF Center. Dr. Nguyen Quang Vinh directly answered many professional questions from the doctors. Additionally, Dr. Vinh emphasized Eurofins GENTIS’s commitment to continue applying advanced testing technologies and strengthening collaboration with assisted reproduction centers to improve patient service quality. At the conclusion of the session, MSc. MD. Nguyen Duy Phuong praised the expert team’s professional sharing and expressed the hope that both parties will continue to enhance cooperation in the future to provide more effective reproductive solutions for patients.
The session ended in an open and collaborative atmosphere. This event reaffirms Eurofins GENTIS’s commitment to delivering modern, accurate, and effective genetic testing solutions, contributing to increased opportunities for many Vietnamese families to become parents.

            [content_more] => 
            [meta_title] => Eurofins GENTIS updates PGT-FAST and GEN28 tests at Hanoi General Hospital IVF center
            [meta_description] => center
Recently, a delegation of experts from Eurofins GENTIS, led by Dr. Nguyen Quang Vinh (Director of Eurofins GENTIS Testing Center), held a professional working session with the doctors and nurses of the Hanoi General Hospital Assisted Reproduction 
            [meta_keyword] => GENTIS,PGT-FAST,GEN28
            [thumbnail_alt] => 
            [post_id] => 1414
            [category_id] => 15
        )

    [7] => stdClass Object
        (
            [id] => 1408
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => c297db27af2f2171783e.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 0
            [displayed_time] => 2026-02-06
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2026-02-06 09:54:55
            [updated_time] => 2026-02-27 13:51:10
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => Summary-of-5-hereditary-cancer-testing-packages-at-Eurofins-GENTIS
            [title] => Summary of 5 hereditary cancer testing packages at Eurofins GENTIS
            [description] => Cancer is one of the leading causes of death worldwide. Numerous studies indicate that 5–10% of cancer cases are associated with hereditary factors, resulting from gene mutations that can be passed down from one generation to the next. Hereditary cancer testing helps identify risks early, enabling the development of appropriate monitoring, prevention, and medical intervention strategies.
            [content] => 
Understanding the growing demand for genetic screening in the community, Eurofins GENTIS has developed five hereditary cancer testing packages ranging from basic to advanced levels, tailored to different individuals, age groups, and family histories.
Why consider hereditary cancer testing?
Unlike conventional tests that detect cancer after it develops, hereditary cancer testing focuses on genetic analysis to determine cancer risk before clinical symptoms appear.
Key benefits include:

Early detection of potential hereditary cancer risks
Proactive development of personalized screening plans
Support for physicians in prevention and treatment counseling
Provision of valuable genetic information for family members
Reduced psychological burden through better understanding of personal health risks


With internationally standardized laboratories and an experienced team of genetic experts, Eurofins GENTIS delivers accurate, reliable testing solutions tailored to the Vietnamese population.

Summary of 5 hereditary cancer testing packages at Eurofins GENTIS
LADY - CARE: Hereditary cancer testing package for women
LADY - CARE is specifically designed for women, focusing on cancers with high incidence rates and strong hereditary associations.

Analysis of 10 genes
Screening for hereditary breast cancer, ovarian cancer, and colorectal cancer


Suitable for:

Women with a family history of breast, ovarian, or colorectal cancer
Women who wish to proactively assess hereditary cancer risk
Women of reproductive or middle age


LADY - CARE helps women better understand their genetic risks and develop appropriate medical monitoring and intervention plans to enhance quality of life.

MEN - CARE: Hereditary cancer screening solution for Men
Men also face various cancers influenced by hereditary factors, particularly prostate and gastrointestinal cancers.

Analysis of 10 genes

Screening for hereditary prostate cancer, colorectal cancer, and gastric cancer


Suitable for:

Men with a family history of related cancers

Middle-aged men or those with high-risk lifestyles or environmental exposures

Individuals seeking proactive genetic health screening


MEN - CARE is an important step in early cancer risk detection, enabling long-term prevention and medical follow-up.

PRE - CARE: Expanded screening for 15 hereditary cancers
PRE - CARE is an extended hereditary cancer testing package for individuals seeking more comprehensive risk assessment.

Analysis of mutations in 17 genes
Screening for 15 hereditary cancers, including: lung, stomach, breast, ovarian, colorectal, pancreatic, kidney, prostate, thyroid, skin, endometrial cancers, paraganglioma, retinoblastoma, pheochromocytoma, and multiple endocrine neoplasia


Suitable for:

Individuals with family histories of multiple cancer types
Those seeking expanded hereditary cancer screening
Individuals planning marriage or childbirth



PRO - CARE: Advanced hereditary cancer testing package
PRO - CARE provides a comprehensive overview of hereditary cancer risks.

Analysis of mutations in 133 genes

Screening for 30 hereditary cancers, including: lung, stomach, breast, ovarian, colorectal, pancreatic, kidney, prostate, thyroid, skin, endometrial, liver, bladder, head and neck, esophageal, biliary tract, small intestine, brain, bone, parathyroid cancers; acute leukemia (blood cancer); rhabdomyosarcoma; pituitary adenoma; neuroblastoma; neurofibroma; and multiple myeloma


Suitable for:

Individuals at high risk of cancer
Families with multiple affected members
Those requiring comprehensive genetic evaluation for long-term monitoring



DIAMOND - CARE: The most comprehensive genetic testing package
DIAMOND - CARE is the most advanced and comprehensive package at Eurofins GENTIS, combining hereditary cancer screening with inherited chronic disease testing.

Total analysis of 177 genes associated with 69 hereditary chronic diseases and cancers, including:



 10 genes – 9 common autosomal recessive disorders:
 Alpha Thalassemia, Beta Thalassemia, G6PD deficiency, Phenylketonuria (PKU), Galactose metabolism disorder, Citrin deficiency–related cholestasis, 5-Alpha Reductase deficiency–related male sex development disorder, Pompe disease, Wilson disease
 133 genes – Screening for 30 hereditary cancers (entire PRO - CARE panel)
 34 genes – 30 hereditary syndromes and chronic conditions:
 20 cardiovascular diseases, 5 connective tissue disorders, and 5 endocrine–metabolic disorders

DIAMOND - CARE is especially suitable for individuals seeking a comprehensive evaluation of hereditary health risks for themselves and their families.
With advanced gene sequencing technology, strict quality control processes, and a highly experienced team of experts, Eurofins GENTIS is committed to delivering accurate, reliable, and clinically valuable results.
Hereditary cancer testing is not just a test — it is a proactive step toward early prevention, appropriate monitoring, and personalized healthcare.
Contact Eurofins GENTIS via hotline 1800 2010 for detailed consultation and to choose the most suitable testing package for you and your family.

            [content_more] => 
            [meta_title] => Summary of 5 hereditary cancer testing packages at Eurofins GENTIS
            [meta_description] => Cancer is one of the leading causes of death worldwide. Numerous studies indicate that 5–10% of cancer cases are associated with hereditary factors, resulting from gene mutations that can be passed down from one generation to the next. Hereditary cancer t
            [meta_keyword] => GENTIS,genetic disorder
            [thumbnail_alt] => 
            [post_id] => 1408
            [category_id] => 15
        )

)